Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate (Q44514988)

3 December 2017

Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate (English)

1 reference

3 December 2017

1

1 reference

3 December 2017

Fabio Monica

14

0 references

Vittorio Terruzzi

object named as

Vittorio Terruzzi

10

0 references

author name string

Luigi Solmi

2

1 reference

3 December 2017

Silvano Loperfido

3

1 reference

3 December 2017

Pietro Leo

4

1 reference

3 December 2017

Virginia Festa

5

1 reference

3 December 2017

Angelo Belmonte

6

1 reference

3 December 2017

Fulvio Spirito

7

1 reference

3 December 2017

Michele Silla

8

1 reference

3 December 2017

Giovambattista Forte

9

1 reference

3 December 2017

Giorgio Marenco

11

1 reference

3 December 2017

Enrico Ciliberto

12

1 reference

3 December 2017

Antonio Sabatino

13

1 reference

3 December 2017

Maria Rita Magnolia

15

1 reference

3 December 2017

Francesco Perri

16

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Clinical Gastroenterology and Hepatology

3 December 2017

1 reference

3 December 2017

2

1 reference

3 December 2017

8

1 reference

3 December 2017

713-718

1 reference

Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Short-term prophylactic prevention of post-ERCP pancreatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Complications of endoscopic biliary sphincterotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Grading ERCPs by degree of difficulty: a new concept to produce more meaningful outcome data

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Endoscopic sphincterotomy complications and their management: an attempt at consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Acute pancreatitis: value of CT in establishing prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Complications of ERCP

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

Toward improving outcomes of ERCP

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900295-2

7 January 2021

10.1016/S1542-3565(04)00295-2

Identifiers

DOI

1 reference

3 December 2017

1 reference